



Dated: September 26, 2026

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES; BSE: 532482

Sub: Intimation of Schedule of Webinar

Dear Sir/mam,

Pursuant to provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that, IIFL Capital is organizing a webinar on September 29, 2026, at 4:30 p.m. to discuss the Company's transformation journey.

The webinar details and registration link are enclosed with this letter.

Thanking You.

Yours sincerely,

For GRANULES INDIA LIMITED

**CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)**

Encl: Details of the Webinar

REGISTERED OFFICE

Granules India Limited

CIN: L24110TG1991PLC012471

15th Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad – 500084, Telangana, India

Contact Us: Tel: +91-40-69043500 | Fax: +91-40-23115145 | mail@granulesindia.com

Granules India 2.0

Comprehensive Transformation Underway

Key growth engines: Controlled substances | Complex formulations & injectables | Oncology | FTF opportunities | Peptide CDMO

Granules is moving beyond its legacy generics franchise, with formulations now accounting for ~75% of revenue and a sharp reduction in dependence on its legacy-5 portfolio (from ~85% in FY23 to <50% in FY26). The company is targeting further growth through controlled substances, complex formulations, oncology, first-to-file/Para IV US opportunities and peptide CDMO.

We invite you to join an exclusive interaction with Granules' promoter and senior mgmt team to understand:

Controlled substances: Can Granules sustain momentum in a highly regulated market where DEA quotas, supply reliability and compliance create structural barriers?

Complex formulations & injectables: What is the roadmap for more complex products, including potential injectables, and how could these reshape the portfolio and margins?

Oncology: How can Granules monetise its existing gross block, product pipeline and potential 180-day exclusivity opportunities from FY28?

FTF opportunities: What is the size and quality of Granules' first-to-file/Para IV pipeline, and where does the company see meaningful opportunities?

Peptide CDMO: How is Granules building its peptide CDMO platform through Senn, what is the opportunity across peptides/oligos/ADCs, and what could drive the targeted USD100m revenue opportunity over the next 4-5 years?

Transformation: How will the evolving business mix translate into revenue growth and margin expansion over the next 3–5 years?

Kindly register for the webinar for a focused discussion on the key building blocks of Granules' next phase of growth.

Date: 29th Sep 2026

Tuesday

Time:

4:30pm IST,

12 noon BST,

7am ET, 7pm HKT

**Register
now!**